Business Context and Reporting Period
Company: Firefly Neuroscience, Inc. (Ticker: AIFF)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: Firefly is an AI technology company developing the Brain Network Analytics (BNA) Platform, an FDA-510(k) cleared software tool that analyzes EEG data to assist in diagnosing and treating mental illnesses and neurological disorders. The company operates in the pre-commercial stage, focusing on commercialization to U.S. neurologists and partnerships with pharmaceutical companies for drug development support.
Corporate Structure: The company became public via a reverse merger with WaveDancer, Inc., closing on August 12, 2024. The transaction was accounted for as a reverse recapitalization.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $108 | $498 |
| Operating Expenses | $10,162 | $3,576 |
| Operating Loss | $(10,054) | $(3,078) |
| Net Loss | $(10,460) | $(2,603) |
| Cash Flow from Operations | $(6,155) | $(2,172) |
| Cash Flow from Financing | $6,299 | $4,643 |
| Cash and Equivalents (Year End) | $1,810 | $2,143 |
| Accumulated Deficit | $(87,084) | $(76,624) |
Liquidity: As of December 31, 2024, the company held $1.81 million in cash. Total current liabilities were $4.98 million, resulting in a working capital deficit. The company has an accumulated deficit of $87.1 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 78% to $108,000 from $498,000 in 2023, primarily due to the recognition of deferred revenue in the prior year that was not repeated in 2024.
- Expense Surge: Total operating expenses increased 184% to $10.2 million.
- R&D: Increased 164% to $1.95 million, driven by the vesting of management options (47% of increase) and additional internal resources.
- G&A: Increased 179% to $6.13 million, largely due to one-time costs associated with the Merger (legal fees, warrant vesting, audit fees) and public company compliance costs.
- Impairment: A one-time impairment charge of $874,000 was recorded for capitalized software upgrades no longer expected to be utilized.
- Capital Structure: The company completed a reverse merger and a concurrent Private Placement (PIPE) raising approximately $3.5 million. It also entered into a $2.4 million convertible promissory note in December 2024.
Outlook, Risks, and Contingencies
Going Concern: The independent auditor has issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses, has minimal revenue, and requires significant additional capital to fund operations and commercialization efforts.
Outlook and Strategy:
- The company plans to launch commercial sales of the BNA Platform in 2025, targeting U.S. neurologists and pharmaceutical partners.
- Management expects to continue incurring negative cash flows for the next 12 months and potentially 2-4 years until commercialization is successful.
- Subsequent to year-end, the company raised approximately $10.4 million through warrant exercises and share sales (February-March 2025).
Key Risks:
- Capital Adequacy: Failure to raise additional capital could force the company to curtail operations.
- Commercialization: Success depends on clinician adoption of the BNA Platform and reimbursement from third-party payors.
- Regulatory: Compliance with FDA regulations and potential changes in healthcare laws (including potential impacts from the Department of Government Efficiency).
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding IT general controls and segregation of duties.
- Geopolitical: Operations in Israel expose the company to risks related to regional conflict and military service obligations of employees.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.4 million raised in early 2025 against the projected burn rate for 2025 commercialization efforts.
- Revenue Recognition: Confirm the nature of the $108k revenue and the timeline for recurring revenue generation from the BNA Platform.
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in ITGC and segregation of duties to ensure reliable future financial reporting.
- Dilution: Assess the impact of the Equity Line of Credit (ELOC) with Arena (up to $10M) and outstanding warrants/options on existing shareholder value.
- Regulatory Status: Verify the status of FDA 510(k) clearance maintenance and any new submissions required for expanded indications.